130 related articles for article (PubMed ID: 7805040)
1. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.
Harpole DH; Herndon JE; Wolfe WG; Iglehart JD; Marks JR
Cancer Res; 1995 Jan; 55(1):51-6. PubMed ID: 7805040
[TBL] [Abstract][Full Text] [Related]
2. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ
Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
Wang Y; Zhang XR; Fu J; Tan W; Zhang W
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
[TBL] [Abstract][Full Text] [Related]
4. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
5. Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer.
Yu CJ; Shun CT; Yang PC; Lee YC; Shew JY; Kuo SH; Luh KT
Am J Respir Crit Care Med; 1997 Apr; 155(4):1419-27. PubMed ID: 9105088
[TBL] [Abstract][Full Text] [Related]
6. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC
Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915
[TBL] [Abstract][Full Text] [Related]
8. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
9. Survival after pathological stage IA nonsmall cell lung cancer: tumor size matters.
Birim O; Kappetein AP; Takkenberg JJ; van Klaveren RJ; Bogers AJ
Ann Thorac Surg; 2005 Apr; 79(4):1137-41. PubMed ID: 15797040
[TBL] [Abstract][Full Text] [Related]
10. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3 cm or less: visceral pleural invasion did not influence overall and disease-free survival.
Hung JJ; Wang CY; Huang MH; Huang BS; Hsu WH; Wu YC
J Thorac Cardiovasc Surg; 2007 Sep; 134(3):638-43. PubMed ID: 17723811
[TBL] [Abstract][Full Text] [Related]
14. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer.
Harpole DH; Richards WG; Herndon JE; Sugarbaker DJ
Ann Thorac Surg; 1996 May; 61(5):1470-6. PubMed ID: 8633961
[TBL] [Abstract][Full Text] [Related]
16. [Retinoid expression (RARbeta and CRBP1) in non-small-cell lung carcinoma].
Mauro LV; Dalurzo M; Smith D; Lastiri J; Vasallo B; Joffei EB; Pallotta MG; Puricelli L
Medicina (B Aires); 2008; 68(3):205-12. PubMed ID: 18689151
[TBL] [Abstract][Full Text] [Related]
17. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
18. [Study of prognostic factors in patients with stage I non-small cell lung cancer].
Jiang ZQ; Jiang GL; Shi DR; Zhang RX; Fu XL; Qian H
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):364-8. PubMed ID: 15312349
[TBL] [Abstract][Full Text] [Related]
19. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas.
Yi ES; Harclerode D; Gondo M; Stephenson M; Brown RW; Younes M; Cagle PT
Mod Pathol; 1997 Feb; 10(2):142-8. PubMed ID: 9127320
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]